Antenatal Corticosteroids for Fetal Lung Maturity: Betamethasone vs Dexamethasone Guide

Introduction: Antenatal Corticosteroids as a Cornerstone of Perinatal Medicine

Antenatal corticosteroid (ACS) administration is arguably the single most impactful intervention in perinatal medicine, reducing neonatal mortality by 31%, respiratory distress syndrome (RDS) by 34%, intraventricular hemorrhage (IVH) by 46%, and necrotizing enterocolitis (NEC) by 54%. Since the landmark Liggins and Howie trial in 1972, ACS therapy has become standard of care worldwide. In India, where preterm birth accounts for 35% of neonatal deaths and an estimated 3.5 million preterm deliveries occur annually, optimizing ACS use is a national health priority endorsed by the National Neonatology Forum (NNF).

This guide provides a comprehensive clinical comparison of betamethasone and dexamethasone, examines dosing protocols, explores the cellular mechanisms of lung maturation, and addresses the Indian clinical context including drug availability, cost considerations, and NNF protocols for ACS administration.

Mechanism of Action: How Corticosteroids Mature Fetal Lungs

Surfactant System Activation

Corticosteroids exert their primary lung-maturing effects through glucocorticoid receptor activation in fetal type II pneumocytes. The molecular cascade involves nuclear translocation of the glucocorticoid-receptor complex, binding to glucocorticoid response elements (GREs) in target genes, and upregulation of key surfactant components.

• Surfactant protein gene expression: SP-A, SP-B, and SP-C transcription increases 3-5 fold within 24 hours of steroid exposure, with SP-B being the most critical for surface-tension reduction.
• Phospholipid synthesis: Dipalmitoylphosphatidylcholine (DPPC), the primary surface-active phospholipid, production increases through upregulation of fatty acid synthase and cholinephosphate cytidylyltransferase enzymes.
• Lamellar body maturation: Corticosteroids accelerate the packaging and secretion of surfactant from lamellar bodies into the alveolar space, increasing the lecithin-to-sphingomyelin (L/S) ratio.

Structural Lung Maturation

Beyond surfactant production, corticosteroids induce profound structural changes in the developing lung architecture that are equally important for postnatal respiratory function.

1. Alveolar septal thinning: Corticosteroids reduce mesenchymal tissue volume, thinning the air-blood barrier and improving gas exchange efficiency.
2. Sodium channel upregulation: Epithelial sodium channel (ENaC) expression increases, facilitating the switch from fluid secretion to fluid absorption at birth, which is critical for postnatal lung fluid clearance.
3. Antioxidant enzyme induction: Superoxide dismutase (SOD), catalase, and glutathione peroxidase are upregulated, protecting the preterm lung against oxygen toxicity.
4. Vascular remodeling: Pulmonary vascular smooth muscle responsiveness to oxygen improves, supporting the postnatal decrease in pulmonary vascular resistance.

Betamethasone vs Dexamethasone: Clinical Comparison

Parameter	Betamethasone	Dexamethasone
Dosing regimen	12 mg IM x 2 doses, 24 hours apart	6 mg IM x 4 doses, 12 hours apart
Formulation	Mixture of phosphate + acetate (sustained release)	Phosphate only (short-acting)
Duration to complete course	24 hours	36 hours
Placental transfer	High (11-beta-HSD2 resistant)	High (11-beta-HSD2 resistant)
RDS reduction	34%	33%
IVH reduction	35-46%	35-46%
Neonatal death reduction	31%	31%
Cost in India (approx.)	INR 80-150 per course	INR 20-50 per course
Availability in India	Variable, sometimes limited	Widely available

Why Both Agents Work: Fluorinated Corticosteroid Pharmacology

Both betamethasone and dexamethasone are fluorinated corticosteroids that resist inactivation by placental 11-beta-hydroxysteroid dehydrogenase type 2 (11-beta-HSD2), the enzyme that normally converts cortisol to inactive cortisone. This resistance ensures that active drug reaches the fetal compartment at therapeutic concentrations. Non-fluorinated steroids like prednisolone and hydrocortisone are inactivated by this placental enzyme and are therefore ineffective for fetal lung maturation.

Clinical Outcome Differences

The Cochrane systematic review and subsequent meta-analyses show no statistically significant difference in the primary outcome of RDS between the two agents. However, some observational data suggest subtle differences favoring betamethasone for certain outcomes, particularly a trend toward lower periventricular leukomalacia (PVL) rates. The sustained-release acetate component of betamethasone may provide more stable fetal drug levels compared to the pulsatile exposure from four dexamethasone doses.

Dosing Protocols and Timing Considerations

Standard WHO and NNF India Protocol

The World Health Organization and NNF India recommend a single course of ACS for all women at risk of preterm delivery between 24 and 34 weeks of gestation. The preferred protocol in India, given drug availability considerations, is dexamethasone 6 mg IM every 12 hours for 4 doses. When betamethasone is available, 12 mg IM repeated once after 24 hours is the alternative protocol.

NNF India Recommendation: Antenatal corticosteroids should be administered in any facility managing high-risk pregnancies, including primary health centers, when preterm delivery is anticipated within 7 days. Dexamethasone is the preferred agent in Indian public health settings due to universal availability and lower cost. A single course is recommended; rescue courses should only be considered at tertiary centers after multidisciplinary discussion.

The Timing Window: When Do Steroids Work Best?

The optimal benefit of ACS occurs when delivery happens 24 hours to 7 days after the first dose. The onset of action begins within 2-4 hours, with measurable surfactant production increases by 8 hours. Clinical studies demonstrate that benefits diminish after 7 days from the last dose, though some protection persists up to 14 days. This timing window presents a clinical challenge, as predicting preterm delivery timing is inherently uncertain.

Extended Indications: Late Preterm and Periviable Gestations

Late Preterm Steroids (34-36 Weeks)

The ALPS (Antenatal Late Preterm Steroids) trial demonstrated that betamethasone at 34 to 36 weeks reduced neonatal respiratory complications from 14.4% to 11.6%. However, neonatal hypoglycemia increased significantly (24% vs 15%), requiring enhanced glucose monitoring. ACOG endorses late preterm steroids with specific criteria; NNF India currently does not recommend routine late preterm ACS outside of research protocols, citing concerns about hypoglycemia in settings with variable monitoring capacity.

Periviable Gestations (22-24 Weeks)

At the border of viability, ACS use is more controversial. ACOG recommends ACS as early as 23+0 weeks when active neonatal resuscitation is planned. At 22 weeks, the evidence is limited and the decision should be individualized. In India, where neonatal intensive care capacity at extreme prematurity is concentrated in select tertiary centers, ACS at periviable gestations is generally recommended from 24 weeks, with earlier administration at centers with established periviable care programs.

Neonatal Effects and Safety Profile

Beneficial Neonatal Outcomes

The well-documented neonatal benefits of a single ACS course include the following reductions in morbidity and mortality.

• Respiratory distress syndrome: 34% reduction (NNT = 11 for prevention of one case)
• Intraventricular hemorrhage: 46% reduction, with particular benefit for severe grades III-IV IVH
• Necrotizing enterocolitis: 54% reduction in confirmed NEC cases
• Neonatal mortality: 31% reduction in the first 28 days of life
• Need for mechanical ventilation: Significantly reduced duration and peak ventilator pressures

Short-Term Neonatal Side Effects

A single ACS course has a favorable safety profile, though clinicians should anticipate transient neonatal effects that require monitoring.

Effect	Mechanism	Duration	Clinical Significance
HPA axis suppression	Negative feedback on fetal ACTH	24-48 hours	Transient; rarely clinically significant
Leukocytosis	Demargination of neutrophils	48-72 hours	May confound sepsis evaluation
Hyperglycemia	Gluconeogenesis stimulation	24-48 hours	More significant with late preterm steroids
Reduced FHR variability	CNS effects of corticosteroids	24-72 hours	Can mimic fetal distress on CTG; awareness essential
Reduced birth weight	Water and sodium retention decrease	Transient	Only significant with multiple courses

Long-Term Safety: Follow-Up Studies

Multiple long-term follow-up studies, including the original Liggins cohort followed to age 30, demonstrate no adverse neurodevelopmental outcomes from a single ACS course. Cognitive function, behavior, and metabolic parameters at school age and adulthood are not significantly different between exposed and unexposed groups. However, multiple repeated courses have been associated with reduced head circumference and birth weight, prompting guidelines to limit ACS to a single course with, at most, one rescue course.

Indian Clinical Context: Implementation Challenges

ACS Coverage Rates in India

Despite strong evidence and guideline endorsement, ACS coverage in India remains suboptimal. National surveys estimate that only 40-50% of eligible preterm deliveries receive ACS, with rates as low as 15-20% in rural and primary healthcare settings. Barriers include delayed recognition of preterm labor, lack of drug availability at peripheral centers, hesitancy due to steroid-related misconceptions, and delayed referral to higher facilities.

Strategies to Improve ACS Coverage

1. Drug availability: Ensuring dexamethasone injection (the more affordable and available option) is stocked at all delivery points, including primary health centers and community health centers.
2. Training programs: NNF and FOGSI conduct Skilled Birth Attendant (SBA) training that includes ACS administration protocols for healthcare workers at all levels.
3. Quality indicators: The Government of India's LaQshya program includes ACS coverage as a quality metric for labor rooms and maternity operation theatres.
4. Community awareness: Educating pregnant women about the benefits of ACS during antenatal visits, particularly in preterm-risk populations, helps facilitate timely administration.

Rescue Courses and Repeat Dosing

The question of repeat ACS courses remains one of the most debated topics in perinatal medicine. If delivery has not occurred 7-14 days after the initial course and preterm delivery risk persists, a single rescue course may be considered. The MACS (Multiple Courses of Antenatal Corticosteroids) trial showed modest short-term respiratory benefit from repeat courses but concerning reductions in birth weight and head circumference. NNF India and ACOG recommend limiting repeat courses to one additional course, with careful documentation of the risk-benefit assessment. HEAMAC neonatal monitoring resources can support post-discharge follow-up for neonates exposed to multiple ACS courses who may benefit from enhanced growth and developmental surveillance.

Conclusion: Optimizing ACS Use for Every Preterm Neonate in India

Antenatal corticosteroids remain the most effective and cost-effective intervention for reducing preterm neonatal morbidity and mortality. In India, dexamethasone is the pragmatic first choice given its wide availability and low cost. The priority for Indian perinatal care is not choosing between agents but ensuring that every eligible preterm pregnancy receives a timely ACS course. Achieving this requires strengthening drug supply chains, training healthcare workers across all facility levels, and monitoring ACS coverage as a key perinatal quality indicator. With structured neonatal follow-up supported by resources like HEAMAC, the full benefits of ACS therapy can be realized for millions of Indian preterm neonates.